Kalzitoninbestimmung zur Frühdiagnose des medullären Schilddrüsenkarzinoms
Author:
- 13 June 2010
- journal article
- abstracts
- Published by Springer Nature in Der Chirurg
- Vol. 81 (7) , 620-626
Abstract
Kalzitonin ist ein sensitiver Marker für das medulläre Schilddrüsenkarzinom (MTC). Durch frühe Erkennung und chirurgische Therapie kann die Prognose des MTC verbessert werden. In der diagnostischen Evaluation von Schilddrüsenknoten wird daher die routinemäßige Kalzitoninbestimmung empfohlen. Bei einem erhöhten basalen Serumkalzitonin (>20 pg/ml) ist ein Bestätigungstest sinnvoll, um den positiven Vorhersagewert für ein MTC insbesondere bei kleinen Tumoren zu erhöhen. Eine definitive Unterscheidung von Mikro-MTC (100 pg/ml werden aufgrund des hohen Karzinomrisikos als Indikation zur Thyreoidektomie angesehen. Der Nachweis eines sehr hohen basalen und stimulierten Kalzitonins ist praktisch beweisend für ein MTC, mit praktischen Konsequenzen für die Operationsplanung. Calcitonin is considered to be a sensitive marker for medullary thyroid cancer (MTC) therefore early detection and surgical treatment may help to improve the clinical prognosis of MTC. Routine calcitonin measurement has therefore been recommended in the diagnostic evaluation of patients with nodular thyroid disease. In the case of elevated serum calcitonin (>20 pg/ml) stimulation testing is recommended to improve the predictive power for MTC particularly in patients with small nodules. Serum calcitonin measurement cannot reliably discriminate between micro-MTC (<10 mm) and C cell hyperplasia. In patients with stimulated calcitonin levels exceeding 100 pg/ml thyroidectomy is recommended because of a high inherent risk of MTC. Highly elevated basal and stimulated serum calcitonin levels are strongly suggestive of MTC with practical implications for surgical management.Keywords
This publication has 30 references indexed in Scilit:
- Schilddrüsenkarzinom – Klinik und DiagnostikDer Onkologe, 2010
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- Medullary Thyroid Cancer: Management Guidelines of the American Thyroid AssociationThyroid®, 2009
- Calculation and Validation of a Plasma Calcitonin Limit for Early Detection of Medullary Thyroid Carcinoma in Nodular Thyroid DiseaseThyroid®, 2009
- Sporadic hypercalcitoninemia: clinical and therapeutic consequencesEndocrine-Related Cancer, 2009
- Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smokingEuropean Journal of Endocrinology, 2007
- Early Diagnosis and Curative Therapy of Medullary Thyroid Carcinoma by Routine Measurement of Serum Calcitonin in Patients with Thyroid DisordersThyroid®, 2005
- Increased calcitonin level in thyroid nodules without medullary carcinomaBritish Journal of Surgery, 2005
- Calcitonin Measurement to Detect Medullary Thyroid Carcinoma in Nodular Goiter: German Evidence-Based Consensus RecommendationExperimental and Clinical Endocrinology & Diabetes, 2004
- Is medullary thyroid cancer predictable? A prospective study of 86 patients with abnormal pentagastrin testsSurgery, 1999